A method for whole exon sequencing of the EMP3 gene encoding human erythrocyte MAM blood type

Through segmented PCR amplification and whole exon sequencing methods, the difficulties of complete amplification and sequencing of EMP3 genes were solved, and tools were provided for MAM blood type gene polymorphism research were evaluated, and the frequency of MAM antigen expression was promoted, which promoted clinical Development of blood transfusion medicine and genetically related diseases.

CN118086475BActive Publication Date: 2024-11-19NANJING DRUM TOWER HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211490693.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-25
Publication Date
2024-11-19
Estimated Expiration
2042-11-25

AI Technical Summary

Technical Problem

The existing technology lacks effective methods to fully amplify and sequence the gene EMP3 of human erythrocyte MAM blood type system, which makes it difficult to study the polymorphism and allelic variants of MAM blood type genes, and there is little knowledge of the distribution of MAM blood type at home and abroad. , affect the prevention and treatment of fetal and neonatal hemolytic diseases.

Method used

Segmented PCR amplification and whole exon sequencing methods are used to design specific primers to segment the EMP3 gene amplification and sequencing, and obtain its complete nucleotide sequence, which is applied to MAM blood type gene polymorphisms and novels. Lex variant study.

Benefits of technology

Complete amplification and sequencing of EMP3 genes is achieved, providing tools for research on polymorphisms of MAM blood type genes, enabling exploration of new allelic variants, assessing the frequency of MAM antigen expression, and thus evaluating its response and correlation with hemolytic transfusions. The relationship between diseases has promoted the development of clinical blood transfusion medicine and genetically related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118086475B_ABST
    Figure CN118086475B_ABST
Patent Text Reader

Abstract

The present application is applied to the application research fields such as encoding human erythrocyte MAM blood type gene polymorphism and exploring new allele variation. Based on the sequence characteristics of the MAM blood type antigen encoding gene EMP3, a method for whole exon sequencing of the EMP3 gene is disclosed. The sequencing method designs four sets of amplification primers and several sequencing primers for amplified fragments. First, the human erythrocyte MAM blood type gene EMP3 is amplified by designing amplification primers. Combined with the proposed primer combination, the sequencing technology can accurately obtain the whole exon nucleotide sequence of the target gene, which can be used to determine the sequence of the MAM blood type encoding gene and / or discover unknown variations.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of biomedical technology, and proposes a method for whole exon sequencing of the EMP3 gene encoding the human erythrocyte MAM blood type, and particularly relates to a method for segmented amplification and whole exon sequencing of the EMP3 gene, which can completely amplify the EMP3 gene and completely sequence its exons, and is applied to applied research fields such as MAM blood type gene polymorphism and exploration of new allele variations. Background Art

[0002] The MAM blood group system is one of the blood group systems officially named by the International Society of Blood Transfusion (ISBT) in 2020, numbered ISBT041. Currently, only one antigen has been found in this blood group system, namely the MAM antigen, the encoding gene is EMP3, located at 19q13.33, with a total length of 5002bp and a total of 6 exons. The coding region is located from exon 3 to exon 6. The encoded product is epithelial membrane proteins 3 (EMP3), which is a 18429kDa multi-channel membrane protein with four transmembrane domains and two N-linked glycosylation sites. The molecular structure has characteristics such as protein kinase C phosphorylation sites; it is a member of the peripheral myelin protein 22-kDa (PMP22) superfamily. MAM antigen-antibody reaction can cause severe hemolytic disease of the fetus and newborn (HDFN). Hemolytic disease of the fetus and neonate refers to the incompatibility of the blood types of the mother and the fetus, which causes the mother's body to produce specific blood type antibodies against the fetal blood type antigens. These antibodies enter the fetal blood circulation through the placenta and sensitize the fetal red blood cells, leading to alloimmune hemolysis in the fetus or newborn. It mainly causes clinical symptoms such as anemia, jaundice, and hepatosplenomegaly. In severe cases, it can develop into kernicterus or even death.

[0003] The function of the EMP3 gene is not yet fully understood. Studies have shown that it down-regulates and activates the MAPK / ERK signaling pathway in gallbladder cancer, thereby promoting tumor progression, indicating that EMP3 has a certain regulatory role in tumor cell proliferation.

[0004] In 2000, Montgomer et al. published the first case of severe hemolytic disease of the newborn (HDN) caused by MAM antibodies in Transfusion, but whether it will cause hemolytic transfusion reactions has not yet been reported. However, MAM antibodies may shorten the survival time of red blood cells after transfusion of incompatible allogeneic red blood cells, so MAM antibodies are considered to be clinically significant antibodies. In July 2020, the latest research results on the genes encoding MAM blood group antigens were jointly published in Nature Communication through the cooperation of multinational institutions. The study identified the gene encoding epithelial membrane protein 3 (EMP3) as a possible candidate gene through whole exome sequencing. Subsequent sequencing in 10 known MAM-negative individuals also found inactivating mutations in the gene. The study also found that erythroid cells also express this EMP3. Through CRISPR / Cas9 gene editing technology, after silencing the expression of the EMP3 gene in the immortalized human erythroid cell line (BEL-A2), the expression of the MAM antigen also turned negative. In addition, the study also found that EMP3 protein is associated with the stable expression of the cell surface signaling molecule CD44. The proliferation of reticulocytes increased when the precursor red blood cells of MAM-negative individuals were cultured in vitro, indicating that EMP3 plays an important regulatory role in erythroid proliferation. This study confirmed that MAM antigens are expressed by the EMP3 protein encoded by the EMP3 gene, and that EMP3 gene mutations are the molecular basis for the formation of the MAM-negative phenotype.

[0005] At present, there are few studies on the distribution frequency and polymorphism of EMP3-related alleles in the MAM blood type system abroad, and there are no related reports in China. The distribution of MAM blood types among various ethnic groups and regions in my country is still unknown. Therefore, establishing a stable and reliable MAM blood type gene sequencing and analysis method is crucial to enrich my country's rare blood type library and prevent and treat fetal and neonatal hemolytic disease. Summary of the invention

[0006] In view of this, an embodiment of the present application provides a method for amplifying and sequencing all exons of the EMP3 gene encoding the human red blood cell MAM blood type gene, which can completely amplify the EMP3 gene and completely sequence its exons to solve the technical defects existing in the prior art.

[0007] One of the inventions of this application is to provide a method for sequencing all exons of the EMP3 gene encoding human erythrocyte MAM blood type. According to this method, the EMP3 gene is amplified and then sequenced in four parts, each of which is exon 1-3, exon 2-4, exon 4-5, and exon 5-6; specifically, this application uses the nucleotide sequence of the EMP3 gene in the NCBI database (https: / / www.ncbi.nlm.nih.gov / nuccore / NC_000019.10?from=48325552&to=48330553&report=genbank) as the source Data (see Table 1), the sequence of exon 1 is the 1st-59th position of the nucleotide sequence of the EMP3 gene, the sequence of exon 2 is the 440th-502th position of the nucleotide sequence of the EMP3 gene, the sequence of exon 3 is the 1279th-1371th position of the nucleotide sequence of the EMP3 gene, the sequence of exon 4 is the 1970th-2072th position of the nucleotide sequence of the EMP3 gene, the sequence of exon 5 is the 3801th-3941th position of the nucleotide sequence of the EMP3 gene, and the sequence of exon 6 is the 4750th-5002th position of the nucleotide sequence of the EMP3 gene.

[0008] Furthermore, the present application performs PCR amplification reaction on exons 1-3, and the amplification primers adopted are:

[0009] Forward primer EMP13F1: 5'-GCCCAATCTCAAGTCCATGC-3'

[0010] Reverse primer EMP13R: 5′-GCCAGAATGCCTTTAGAGGA-3′;

[0011] Furthermore, the amplified fragments of exons 1-3 were sequenced, and the sequencing primers used were:

[0012] EMP13F1:5'-GCCCAATCTCAAGTCCATGC-3';

[0013] Furthermore, PCR amplification reaction was performed on exons 2-4, and the amplification primers used were:

[0014] Forward primer EMP24F1: 5'-TCGGTAAGTTTCCAGTCCGTT-3'

[0015] Reverse primer EMP24R1: 5'-ACCCCTCACCATTCTCGCTGA-3'

[0016] Furthermore, the amplified fragment of exon 2-4 was sequenced, and the sequencing primers used were:

[0017] EMP24F1:5'-TCGGTAAGTTTCCAGTCCGTT-3'

[0018] EMP35F2:5'-TCTTGGCTCATTGCAACCTT-3'

[0019] Furthermore, PCR amplification reaction was performed on exon 4-5, and the amplification primers used were:

[0020] Forward primer EMP45F: 5'-CCCTTTTAGCTCTACCTCCGAT-3'

[0021] Reverse primer EMP45R: 5'-CTACAAGTCCCAGCAATCCCT-3'

[0022] Furthermore, the amplified fragment of exon 4-5 was sequenced, and the sequencing primers used were:

[0023] EMP45F:5'-CCCTTTTAGCTCTACCTCCGAT-3'

[0024] EMP45R:5'-CTACAAGTCCCAGCAATCCCT-3'

[0025] Furthermore, the amplification primers used for PCR amplification of exon 5-6 are:

[0026] Forward primer EMP56F: 5'-AGCTGGAACTCTGGACCCAC-3'

[0027] Reverse primer EMP56R1: 5'-GACCCCAAATGTTCAGTCCCT-3'

[0028] Furthermore, the sequencing primers used to sequence the amplified fragment of exon 5-6 are:

[0029] EMP56F:5'-AGCTGGAACTCTGGACCCAC-3'

[0030] EMP56S1:5'-GCAAAGGGCTAACTTAATCACAG-3'

[0031] Another inventive point of the present application is the application of the above-mentioned EMP3 whole exon sequencing method in MAM blood type antigen detection.

[0032] The beneficial effects of this application are:

[0033] 1) This application firstly designs amplification primers to amplify the human red blood cell MAM blood type gene EMP3 in segments, and combines the primer combination to accurately obtain the full exon nucleotide sequence of the target gene, which can be used to determine the full exon sequence of the MAM blood type encoding gene and / or discover unknown mutations.

[0034] 2) The EMP3 gene segmented amplification and sequencing method of the present application can be used to completely amplify the EMP3 gene and completely sequence its exons, and can be applied to applied research fields such as MAM blood type gene polymorphism and exploration of new allele variations.

[0035] 3) In the future, population screening can be used to evaluate the frequency of corresponding antigen expression and the relationship between the antigen and hemolytic transfusion reactions, neonatal hemolytic disease and related diseases. This will not only help the development of clinical transfusion medicine, but also be of great significance for the study of gene-related diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 The left side is the agarose gel electrophoresis image after amplification using primer set 1. Figure 1 The three bands on the right are agarose gel electrophoresis images after amplification using primer set 2, primer set 3, and primer set 4, respectively;

[0037] Figure 2 This is the peak diagram of EMP3 exon 1 sequencing;

[0038] Figure 3 This is the peak diagram of EMP3 exon 2 sequencing;

[0039] Figure 4 This is the peak diagram of EMP3 exon 3 sequencing;

[0040] Figure 5 This is the peak diagram of EMP3 exon 4 sequencing;

[0041] Figure 6 This is the peak diagram of EMP3 exon 5 sequencing;

[0042] Figure 7 This is the peak diagram of EMP3 exon 6 sequencing; DETAILED DESCRIPTION

[0043] The four embodiments of the present application are all based on the sequence characteristics of the human red blood cell MAM blood type antigen encoding gene EMP3. A set of four groups of EMP3 gene amplification primers are used to specifically amplify the EMP3 gene fragment through PCR technology, and a method for EMP3 gene amplification and whole exon sequencing is created, which is applied to the research of MAM blood type gene polymorphism, exploration of new mutations and other fields.

[0044] In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the reagents, materials and operating procedures used herein are reagents, materials and conventional procedures widely used in the corresponding fields.

[0045] The preferred examples of the present invention are described below. It should be understood that the preferred examples described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.

[0046] Example 1

[0047] This example uses the following PCR amplification reaction system and conditions for exons 1-3 of the EMP3 gene:

[0048] 1. Primers for amplification of EMP3 exons 1-3:

[0049] Forward primer EMP13F1: 5'-GCCCAATCTCAAGTCCATGC-3'

[0050] Reverse primer EMP13R: 5'-GCCAGAATGCCTTTAGAGGA-3'

[0051] 2. EMP3 exon 1-3 amplification system:

[0052] 5X PCR Buffer (10mM MgSO4) 10μl, dNTP Mix 0.5μl, Phanta Super-Fidelity DNA Polymerase 0.25μl (Nanjing Novozymes Biotechnology Co., Ltd.), EMP13F1 0.5μl, EMP13R 0.5μl, 50-100ng / μl genomic DNA 1μl, add ddH2O to 50μl.

[0053] 3. EMP3 exon 1-3 amplification conditions:

[0054]

[0055] The above primers were used to perform PCR amplification, and the amplified fragments were stained with nucleic acid dyes and subjected to 1% agarose gel electrophoresis. The results were as follows: Figure 1 As shown, this pair of primers can obtain fragments of the target size, and the bands are single and bright, indicating that this pair of primers has very good specificity.

[0056] 4. Purify the gene fragment obtained after amplification of EMP3 exon 1-3:

[0057] The amplified fragment was purified using the AxyPrep PCR purification kit (refer to the instructions of the AxyPrep PCR purification kit for purification steps).

[0058] 5. Sequencing of the purified EMP3 exon 1-3 amplified fragment:

[0059] The purified product was sequenced using the sequencing primer EMP13F1: 5'-GCCCAATCTCAAGTCCATGC-3'.

[0060] The sequencing results were read using Bioedit software. Figure 2 , Figure 3 and Figure 4 As shown, each exon peak graph is single, clear and unambiguous.

[0061] Example 2

[0062] This example targets exons 2-4 of the EMP3 gene and adopts the following PCR amplification reaction system and conditions:

[0063] 1. Primers for amplification of EMP3 exons 2-4:

[0064] Forward primer EMP24F1: 5'-TCGGTAAGTTTCCAGTCCGTT-3'

[0065] Reverse primer EMP24R1: 5'-ACCCCTCACCATTCTCGCTGA-3'

[0066] 2. EMP3 exon 2-4 amplification system:

[0067] 5X PCR Buffer (with 10mM MgSO 4) 10μl, dNTP Mix 0.5μl, Phanta Super-Fidelity DNA Polymerase 0.25μl (Nanjing Novozymes Biotechnology Co., Ltd.), EMP24F1 0.5μl, EMP24R1 0.5μl, 50-100ng / μl genomic DNA 1μl, add ddH2O to 50μl.

[0068] 3. EMP3 exon 2-4 amplification conditions

[0069]

[0070] The above primers were used to perform PCR amplification, and the amplified fragments were stained with nucleic acid dyes and subjected to 1% agarose gel electrophoresis. The results were as follows: Figure 1As shown, this pair of primers can obtain fragments of the target size, and the bands are single and bright, and this pair of primers has very good specificity.

[0071] 4. Purify the gene fragment obtained after amplification of EMP3 exon 2-4:

[0072] The amplified fragment was purified using the AxyPrep PCR purification kit (refer to the instructions of the AxyPrep PCR purification kit for purification steps).

[0073] 5. Sequencing of the purified EMP3 exon 2-4 amplified fragment:

[0074] The purified product was sequenced using the following sequencing primers:

[0075] EMP24F1:5'-TCGGTAAGTTTCCAGTCCGTT-3'

[0076] EMP35F2:5'-TCTTGGCTCATTGCAACCTT-3'

[0077] The sequencing results were read using Bioedit software. Figure 3 , Figure 4 and Figure 5 As shown, each exon peak graph is single, clear and unambiguous.

[0078] Example 3

[0079] This example targets exons 4-5 of the EMP3 gene and adopts the following PCR amplification reaction system and conditions:

[0080] 1. Primers for amplification of EMP3 exon 4-5:

[0081] Forward primer EMP45F: 5'-CCCTTTTAGCTCTACCTCCGAT-3'

[0082] Reverse primer EMP45R: 5'-CTACAAGTCCCAGCAATCCCT-3'

[0083] 2. EMP3 exon 4-5 amplification system:

[0084] 10X PCR Buffer 5μl, dNTP 0.5μl, DMSO 2μl, Fast Start High Fidelity Enzyme 0.25μl (Roche), EMP45F 0.5μl, EMP45R 0.5μl, 50-100ng / μl genomic DNA 1μl, add ddH2O to 50μl.

[0085] 3. EMP3 exon 4-5 amplification conditions

[0086]

[0087] The above primers were used to perform PCR amplification, and the amplified fragments were stained with nucleic acid dyes and subjected to 1% agarose gel electrophoresis. The results were as follows: Figure 1 As shown, this pair of primers can obtain fragments of the target size, and the bands are single and bright, indicating that this pair of primers has very good specificity.

[0088] 4. Purify the gene fragment obtained after amplification of EMP3 exon 4-5:

[0089] The amplified fragment was purified using the AxyPrep PCR purification kit (refer to the instructions of the AxyPrep PCR purification kit for purification steps).

[0090] 5. Sequencing of the purified EMP3 exon 4-5 amplified fragment:

[0091] The purified product was sequenced using the following sequencing primers:

[0092] EMP45F:5'-CCCTTTTAGCTCTACCTCCGAT-3'

[0093] EMP45R:5'-CTACAAGTCCCAGCAATCCCT-3'

[0094] The sequencing results were read using Bioedit software. Figure 5 and Figure 6 As shown, each exon peak graph is single, clear and unambiguous.

[0095] Example 4

[0096] This example targets exons 5-6 of the EMP3 gene and adopts the following PCR amplification reaction system and conditions:

[0097] 1. Primers for amplification of EMP3 exon 5-6:

[0098] Forward primer EMP56F: 5'-AGCTGGAACTCTGGACCCAC-3'

[0099] Reverse primer EMP56R1: 5'-GACCCCAAATGTTCAGTCCCT-3'

[0100] 2. EMP3 exon 5-6 amplification system and conditions:

[0101] 5X PCR Buffer (10mM MgSO4) 10μl, dNTP Mix 0.5μl, Phanta Super-Fidelity DNA Polymerase 0.25μl (Nanjing Novozymes Biotechnology Co., Ltd.), EMP56F 0.5μl, EMP56R 10.5μl, 50-100ng / μl genomic DNA 1μl, add ddH2O to 50μl.

[0102] 3. EMP3 exon 5-6 amplification conditions

[0103]

[0104] The above primers were used to perform PCR amplification, and the amplified fragments were stained with nucleic acid dyes and subjected to 1% agarose gel electrophoresis. The results were as follows: Figure 1 As shown, this pair of primers can obtain fragments of the target size, and the bands are single and bright, indicating that this pair of primers has very good specificity.

[0105] 4. Purify the gene fragment obtained after amplification of EMP3 exon 5-6:

[0106] The amplified fragment was then purified using the AxyPrep PCR purification kit (refer to the instructions for the AxyPrep PCR purification kit for the purification steps).

[0107] 5. Sequencing of the purified EMP3 exon 5-6 amplified fragment:

[0108] The purified product was sequenced using the following sequencing primers:

[0109] EMP56F:5'-AGCTGGAACTCTGGACCCAC-3'

[0110] EMP56S1:5'-GCAAAGGGCTAACTTAATCACAG-3'

[0111] The sequencing results were read using Bioedit software. Figure 6 and Figure 7 As shown, each exon peak graph is single, clear and unambiguous.

[0112] By using the EMP3 gene segmentation amplification and sequencing method of the present application, the EMP3 gene can be completely amplified and its exons can be completely sequenced, and applied to applied research fields such as MAM blood type gene polymorphism and exploration of new allele variation. Since MAM blood type system antigen-negative individuals are relatively rare, in the future we can evaluate the frequency of corresponding antigen expression through population screening, and evaluate the relationship between the antigen and hemolytic transfusion reactions, neonatal hemolytic disease, and related diseases. This will not only contribute to the development of clinical transfusion medicine, but also has important significance for the study of gene-related diseases.

[0113] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention is described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for whole exon sequencing of the EMP3 gene encoding human erythrocyte MAM blood type, It is characterized in that The EMP3 gene was amplified and then sequenced in four parts, the four parts being: exon 1-3, exon 2-4, exon 4-5, and exon 5-6; PCR amplification reaction was performed on exons 1-3, and the amplification primers used were: Forward primer EMP13F1: 5'-GCCCAATCTCAAGTCCATGC-3' Reverse primer EMP13R: 5'-GCCAGAATGCCTTTAGAGGA-3', The amplified fragments of exons 1-3 were sequenced using the following sequencing primers: EMP13F1:5'-GCCCAATCTCAAGTCCATGC-3'; PCR amplification reaction was performed on exons 2-4, and the amplification primers used were: Forward primer EMP24F1: 5'-TCGGTAAGTTTCCAGTCCGTT-3' Reverse primer EMP24R1: 5'-ACCCCTCACCATTCTCGCTGA-3', The amplified fragment of exon 2-4 was sequenced using the following sequencing primers: EMP24F1:5'-TCGGTAAGTTTCCAGTCCGTT-3' EMP35F2:5'-TCTTGGCTCATTGCAACCTT-3'; PCR amplification reaction was performed on exon 4-5, and the amplification primers used were: Forward primer EMP45F: 5'-CCCTTTTAGCTCTACCTCCGAT-3' Reverse primer EMP45R: 5'-CTACAAGTCCCAGCAATCCCT-3', The amplified fragment of exon 4-5 was sequenced using the following sequencing primers: EMP45F:5'-CCCTTTTAGCTCTACCTCCGAT-3' EMP45R:5'-CTACAAGTCCCAGCAATCCCT-3'; PCR amplification reaction was performed on exon 5-6, and the amplification primers used were: Forward primer EMP56F: 5'-AGCTGGAACTCTGGACCCAC-3' Reverse primer EMP56R1: 5'-GACCCCAAATGTTCAGTCCCT-3', sequence the amplified fragment of exon 5-6, and the sequencing primers used are: EMP56F:5'-AGCTGGAACTCTGGACCCAC-3' EMP56S1:5'-GCAAAGGGCTAACTTAATCACAG-3'.

2. Use of the method according to claim 1 in detecting MAM blood group antigens.